Twist Bioscience Corporation (TWST)
NASDAQ: TWST · Real-Time Price · USD
85.47
-3.08 (-3.48%)
At close: Jul 29, 2026, 4:00 PM EDT
84.50
-0.97 (-1.13%)
After-hours: Jul 29, 2026, 4:13 PM EDT
Twist Bioscience Employees
Twist Bioscience had 979 employees as of September 30, 2025. The number of employees increased by 56 or 6.07% compared to the previous year.
Employees
979
Change (1Y)
56
Growth (1Y)
6.07%
Revenue / Employee
$418,263
Profits / Employee
-$83,019
Market Cap
5.32B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 979 | 56 | 6.07% |
| Sep 30, 2024 | 923 | 4 | 0.44% |
| Sep 30, 2023 | 919 | -70 | -7.08% |
| Sep 30, 2022 | 989 | 337 | 51.69% |
| Sep 30, 2021 | 652 | 127 | 24.19% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ICON Public Limited Company | 40,100 |
| Charles River Laboratories International | 19,700 |
| Revvity | 11,000 |
| RadNet | 9,276 |
| Qiagen | 5,700 |
| Sotera Health Company | 3,000 |
| GRAIL | 910 |
| CareDx | 765 |
TWST News
- 13 days ago - Twist Bioscience price target raised to $110 from $80 at Leerink - TheFly
- 14 days ago - Twist Bioscience to Report Fiscal 2026 Third Quarter Financial Results on Monday, August 3, 2026 - Business Wire
- 15 days ago - Twist Bioscience price target raised to $120 from $90 at Canaccord - TheFly
- 23 days ago - Twist Bioscience downgraded to In Line from Outperform at Evercore ISI - TheFly
- 4 weeks ago - Twist Bioscience price target raised to $107 from $60 at Guggenheim - TheFly
- 5 weeks ago - Twist Bioscience price target raised to $95 from $65 at Barclays - TheFly
- 5 weeks ago - Twist Bioscience files automatic mixed securities shelf - TheFly
- 6 weeks ago - Ozempic Linked To Lower Risk Of Violence In New Study - Forbes